Skip to main content

FDA Says Drug Makers Will Stop Producing Fentanyl 'Lollipops'

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 20, 2024.

By Robin Foster HealthDay Reporter

FRIDAY, Sept. 20, 2024 -- Controversial fentanyl lollipops and similar products will no longer be made by drug makers, the U.S. Food and Drug Administration has announced.

Known as TIRF medications, these products contain fentanyl and are used to manage breakthrough pain in cancer patients who have become tolerant to around-the-clock opioid therapy, the FDA said in a statement released this week.

The decision by drug makers to stop selling such medicines follows decades of investigations and lawsuits against the drugmakers that had marketed the fast-acting painkillers too aggressively, CBS News reported.

In 2020, the FDA first tightened prescribing restrictions on the products, in response to data suggesting they were being given to patients who are not opioid-tolerant.

Drugmaker Cephalon had the FDA's approval to market these drugs for years under brand names like Actiq, a sweetened lozenge on a stick, or Fentora, a tablet that dissolves in the mouth.

Generic pharmaceutical manufacturer Teva Pharmaceuticals acquired Cephalon in 2011, when the market for Actiq was worth around $173 million a year, CBS News reported.

Teva officials did not respond Thursday to a request for comment on why it will stop selling the products, CBS News reported.

In 2022, Teva settled lawsuits from state and local governments that had accused the company of promoting Actiq and other powerful fentanyl painkillers for patients without cancer and downplaying addiction risks.

Teva will stop selling the products on Sept. 30, the FDA said.

"FDA did not request this discontinuation. It is important to note that FDA does not manufacture medicine and cannot require a pharmaceutical company to make a medicine, make more of a medicine or change the distribution of a medicine," the agency added.

Sources

  • U.S. Food and Drug Administration, news release, Sept. 16, 2024
  • CBS News

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

U.S. Health Care System Ranks Last Among Wealthy Nations, Report Finds

THURSDAY, Sept. 19, 2024 -- Americans have the worst health care among the world’s wealthy nations, a new report says. People in the United States die the earliest and live...

More Cancer Cases in Areas Where Incarceration Rates Are High: Study

TUESDAY, Sept. 17, 2024 -- Counties and states where jails and prisons are packed are more likely to have higher rates of cancer, new research shows. “These results...

CAR-T Therapy Won't Raise Odds for a Second Cancer, Study Finds

WEDNESDAY, Sept. 11, 2024 -- Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the odds for a secondary cancer...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.